FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/27/2024
Back to search
Official data from USPTO
COMBI-OGAB
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
12
Latest update
06/27/2024
Classification
Registered
Trademark type
Word
Nice classes
42
Filing date
03/31/2023
Registration date
05/28/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/28/2024
Last transaction
05/28/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
JP
Examiner
SWIFT, GILBERT M
Law office
L90
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Synplogen Co., Ltd.
Representatives
ISHIKAWA Taro
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Research and development relating to DNA synthesis technology; technical advisory services relating to DNA synthesis technology; research and development relating to production and analysis of virus vector; technological advisory services relating to production and analysis of virus vector; research and development relating to production and analysis of mRNA; technological advisory services relating to production and analysis of mRNA; research and development relating to gene therapy; technical advisory services relating to gene therapy research; technological advisory services relating to productization of gene therapy products; research and development in the fields of bacteriologycytologyantibody technologychemistryimmunologygene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and developmenttechnical advisory services relating thereto in the fields of proteinantibodyvaccinevirusvirus vectormRNAmicroorganismscells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; technical advisory services relating to genome synthesis technology; research and developmenttechnical advisory services relating thereto in the fields of proteinvaccinevirusvirus vectormRNAantibodymicroorganismscellsall with genome synthesis technology; research and development in the fields of bacteriologycytologyantibody technologychemistryimmunologygene expression systemsall with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testinginspectionresearch of pharmaceuticalsgene therapy productsregenerative medical productscosmetics or foodstuffsall with genome synthesis technology; development of pharmaceuticalsgene therapy productsregenerative medical productscosmetics or foodstuffsall with genome synthesis technology; technical advisory services relating to development of pharmaceuticalsgene therapy productsregenerative medical productscosmetics or foodstuffsall with genome synthesis technology; quality testinginspectionresearch relating to medical treatment or medical technology with genome synthesis technology; testing and research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; research and development relating to production and analysis of virus vector for others; research and development relating to gene therapy products for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; quality testinginspectionresearch in the fields of agriculturelivestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; research and development in the field of gene expression systems; research and development in the fields of microorganisms and cells; research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; bacteriological research; biological research
Publications
History of USPTO decisions and trademark events.
12 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/28/2024
GPNX
NOTIFICATION PROCESSED BY IB
03/12/2024
PUBO
PUBLISHED FOR OPPOSITION
03/12/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/21/2024
NPUB
NOTICE OF PUBLICATION
02/21/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/21/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/01/2024
DOCK
ASSIGNED TO EXAMINER
12/27/2023
MAFR
APPLICATION FILING RECEIPT MAILED
06/27/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/23/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/22/2023
Continuous trademark protection
Get notified about every new filing that threatens COMBI-OGAB or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.